SHARPE·IQStart free
Menu
TodayResearchEarningsToolsPricingSign in
IART reported Third Quarter 2026 results. The stock moved -11.2% on the print.
IARTearnings

Earnings reactions, page 14

Integra LifeSciences Holdings Corporation (IART) Q3 FY2026 earnings

October 21, 2026 · SharpeIQ Research Desk

Reported results

  • Third quarter reported revenues of $411.2 million increased 2.3% on a reported basis and 2.5% on an organic basis compared to the prior year.
  • Third quarter GAAP earnings per diluted share was $0.19, compared to $(0.07) in the prior year.
  • Third quarter adjusted earnings per diluted share was $0.59, compared to $0.54 in the prior year.
  • GAAP gross margin was 51.0%, compared to 51.5% in the third quarter of 2025.
  • Adjusted gross margin was 61.1%, compared to 62.9% in the prior year.
  • Adjusted EBITDA for the third quarter was $79.8 million, or 19.4% of revenue, compared to $78.5 million, or 19.5% of revenue, in the prior year.

Guidance

  • For the fourth quarter of 2026, the company expects reported revenues in the range of $413 million to $433 million, representing a reported decline of -5.2% to -0.5% and an organic decline of -5.1% to -0.4%.
  • For the fourth quarter of 2026, the company expects adjusted earnings per diluted share in the range of $0.61 to $0.71.
  • For the full year 2026, the company expects revenues in the range of $1.634 billion to $1.654 billion, representing reported growth of -0.1% to 1.2% and organic growth of -0.3% to 0.9%.
  • For the full year 2026, the company expects adjusted earnings per diluted share in the range of $2.30 to $2.40.
  • For the full year 2026, the company continues to expect operating cash flow of approximately $190 million to $200 million.

Price and volatility reaction

The stock moved -11.2% on the print. No front-expiry chain was on file, so there is no straddle expected move. 30-day ATM implied volatility moved -4.9 vol points across the event (constant-maturity series — not the front-week crush).

MeasureValueBasis
Close before release13.332026-10-20
Close after release11.842026-10-21
Realised move-11.2%close to close
30d ATM IV change-4.9 vol ptsconstant-maturity series, not the front expiry
Price and volatility reaction. Closes either side of the release. No front-expiry chain on file for a straddle expected move. SharpeIQ — listed option chain and price_history

Source

The figures above come from the earnings release the company filed with the SEC on 2026-10-21 (8-K, Item 2.02). Read the original filing on sec.gov.

See this live in SharpeIQ

IV rank, historical IV and the single-ticker tools. The scanner and AI research are paid plans.

Open IV Rank →